Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings
Xeris Biopharma (XERS) reported $60.1 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 35.4%. EPS of -$0.03 for the same period compares to -$0.10 a year ago.
The reported revenue represents a surprise of -0.81% over the Zacks Consensus Estimate of $60.59 million. With the consensus EPS estimate being -$0.07, the EPS surprise was +57.14%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Xeris Biopharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product Revenue- Gvoke: $23.26 million compared to the $23.90 million average estimate based on five analysts.
- Product Revenue- Keveyis: $11.12 million compared to the $21.19 million average estimate based on five analysts.
- Revenue- Royalty, contract and other: $3.10 million versus the five-analyst average estimate of $1.30 million.
- Revenue- Product revenue, net: $57 million versus $56.26 million estimated by five analysts on average.
- Product Revenue- Recorlev: $22.61 million versus $11.19 million estimated by five analysts on average.
Shares of Xeris Biopharma have returned +2.7% over the past month versus the Zacks S&P 500 composite's -3.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Xeris Biopharma Holdings, Inc. (XERS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available